Pyruvate dehydrogenase complex (PDC) is an important enzyme complex in the body that plays a key role in energy metabolism and the production of ATP. It is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In this article, we will discuss the structure, function, and importance of the pyruvate dehydrogenase complex.
The pyruvate dehydrogenase complex is composed of three different enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide dehydrogenase (E2), and dihydrolipoamide transacetylase (E3). The E1 enzyme is a homodimer composed of two identical subunits, each containing a single active site. The E2 enzyme is a homotetramer composed of four identical subunits, each with a single active site. The E3 enzyme is a homodecamer composed of ten identical subunits, each with a single active site. The three enzymes are held together by non-covalent interactions.
The pyruvate dehydrogenase complex is responsible for the conversion of pyruvate to acetyl-CoA. This reaction involves the oxidation of pyruvate and the reduction of NAD+. The reaction is catalyzed by the E1 enzyme, which is a pyruvate dehydrogenase. The E1 enzyme converts pyruvate to a hydroxyethyl-TPP intermediate, which is then converted to acetyl-CoA by the E2 and E3 enzymes. The E2 enzyme is a dihydrolipoamide dehydrogenase, which catalyzes the oxidation of the hydroxyethyl-TPP intermediate and the reduction of NAD+. The E3 enzyme is a dihydrolipoamide transacetylase, which catalyzes the transfer of the acetyl group from the hydroxyethyl-TPP intermediate to coenzyme A.
The activity of the pyruvate dehydrogenase complex is regulated by several different mechanisms. The activity of the E1 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated. The activity of the E2 enzyme is regulated by allosteric inhibition, in which the enzyme is inhibited by the binding of NADH. The activity of the E3 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated.
The pyruvate dehydrogenase complex is an important enzyme complex that plays a key role in energy metabolism and the production of ATP. The PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In addition, the PDC is also involved in the regulation of fatty acid oxidation and gluconeogenesis.
The pyruvate dehydrogenase complex is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. It is responsible for the conversion of pyruvate to acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. The activity of the PDC is regulated by several different mechanisms, including covalent modification and allosteric inhibition. The PDC is an important enzyme complex that plays a key role in energy metabolism and the production of ATP.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation